<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.neurologylive.com/view/neflamapimod-phase-2a-data-primary-progressive-aphasia-show-exposure-linked-nfl-decline</loc>
      <lastmod>2026-11-19T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Neflamapimod Phase 2a Data in Primary Progressive Aphasia Show Exposure-Linked NfL Decline]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/als-prevention-gene-therapy-and-newborn-screening-at-mda-2027</loc>
      <lastmod>2026-11-19T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/fda-approves-venglustat-first-therapy-neurological-manifestations-type-3-gaucher-disease</loc>
      <lastmod>2026-11-19T15:05:27.872Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:05:27.872Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/defining-treatment-success-in-mg</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Defining Treatment Success in MG]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/addressing-unmet-needs-with-emerging-mg-therapies</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Addressing Unmet Needs with Emerging MG Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/phase-2-spinoza-trial-test-cetp-inhibitor-obicetrapib-apoe-stratified-preclinical-alzheimers</loc>
      <lastmod>2026-11-19T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/fda-approves-cemdisiran-as-new-treatment-generalized-myasthenia-gravis</loc>
      <lastmod>2026-11-18T23:16:47.721Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T23:16:47.721Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/perfuze-receives-fda-clearance-neurosheath-8f-long-sheath</loc>
      <lastmod>2026-11-18T23:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T23:00:00Z</news:publication_date>
        <news:title><![CDATA[Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/levetiracetam-misses-primary-endpoint-early-alzheimer-trial</loc>
      <lastmod>2026-11-18T20:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Levetiracetam Misses Primary Endpoint in Early Alzheimer Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/infarct-size-alone-predict-thrombectomy-outcomes-registry-shows</loc>
      <lastmod>2026-11-18T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Infarct Size Alone Doesn't Predict Thrombectomy Outcomes, Registry Shows]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/mevidalen-misses-primary-endpoint-phase-2-alzheimer-trial</loc>
      <lastmod>2026-11-18T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/beyond-relapses-and-mri-practical-ways-to-monitor-ms-control</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Beyond Relapses and MRI: Practical Ways to Monitor MS Control]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/positioning-b-cell-depleting-therapies-in-the-mg-treatment-sequence</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/pira-in-ms-recognizing-progression-independent-of-relapse-activity</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[PIRA in MS: Recognizing Progression Independent of Relapse Activity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/switching-within-or-across-drug-classes-safely-in-mg</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Switching Within or Across Drug Classes Safely in MG]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/orlando-forum-weighs-dual-antiplatelet-therapy-duration-after-stroke</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Orlando Forum Weighs Dual Antiplatelet Therapy Duration After Stroke]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/neurovoices-brian-lin-fda-approval-gefurulimab-generalized-mg</loc>
      <lastmod>2026-11-18T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T11:00:00Z</news:publication_date>
        <news:title><![CDATA[NeuroVoices: Brian Lin, PhD, on the FDA Approval of Gefurulimab for Generalized Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/ar1001-slows-decline-monotherapy-group-phase-3-alzheimer-trial</loc>
      <lastmod>2026-11-17T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T22:00:00Z</news:publication_date>
        <news:title><![CDATA[AR1001 Slows Decline in Monotherapy Group of Phase 3 Alzheimer Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/fda-approves-adrabetadex-first-therapy-improve-survival-infantile-onset-niemann-pick-disease-type-c</loc>
      <lastmod>2026-11-17T20:08:33.448Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:08:33.448Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.neurologylive.com/view/full-x-tole2-data-detail-azetukalner-dose-dependent-profile-focal-epilepsy</loc>
      <lastmod>2026-11-17T20:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>NeurologyLive - Clinical Neurology News and Neurology Expert Insights</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Full X-TOLE2 Data Detail Azetukalner's Dose-Dependent Profile in Focal Epilepsy]]></news:title>
      </news:news>
	</url></urlset>